Displaying 1 - 20 of 360 results
Released Company Title Industry Topic
24 Jan 2020
07:00 CET
IPSEN Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria Pharmaceuticals Other subject
24 Jan 2020
07:00 CET
IPSEN Le programme clinique d’Ipsen pour le palovarotène dans la fibrodysplasie ossifiante progressive atteint le critère de futilité lors de l’analyse intérimaire prévue au protocole Pharmaceuticals Other subject
17 Jan 2020
07:00 CET
IPSEN Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF Pharmaceuticals Other subject
17 Jan 2020
07:00 CET
IPSEN Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF Pharmaceuticals Other subject
14 Jan 2020
07:00 CET
IPSEN Ipsen nomme le Docteur Steven Hildemann, MD., PhD, en tant que Vice-Président Exécutif, Chief Medical Officer Pharmaceuticals Other subject
14 Jan 2020
07:00 CET
IPSEN Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer Pharmaceuticals Other subject
09 Jan 2020
18:00 CET
IPSEN Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company Pharmaceuticals Other subject
09 Jan 2020
18:00 CET
IPSEN Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Pharmaceuticals Other subject
06 Jan 2020
07:00 CET
IPSEN Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy Pharmaceuticals Other subject
06 Jan 2020
07:00 CET
IPSEN Ipsen : Dysport® (complexe de toxine botulique Clostridium de type A-hémagglutinine) est maintenant approuvé au Royaume-Uni dans le traitement symptomatique de la spasticité des membres supérieurs chez les enfants atteints de paralysie cérébrale Pharmaceuticals Other subject
19 Dec 2019
18:00 CET
IPSEN Ipsen Announces Its Corporate Agenda For 2020 Pharmaceuticals Other subject
19 Dec 2019
18:00 CET
IPSEN Ipsen annonce son calendrier financier 2020 Pharmaceuticals Other subject
18 Dec 2019
07:00 CET
IPSEN Ipsen annonce le départ de son Directeur général David Meek Pharmaceuticals Other subject
18 Dec 2019
07:00 CET
IPSEN Ipsen Announces Departure of David Meek as Chief Executive Officer Pharmaceuticals Other subject
12 Dec 2019
18:00 CET
IPSEN Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Pharmaceuticals Other subject
12 Dec 2019
18:00 CET
IPSEN Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company Pharmaceuticals Other subject
06 Dec 2019
07:00 CET
IPSEN Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies Pharmaceuticals Other subject
06 Dec 2019
07:00 CET
IPSEN Ipsen initie une suspension clinique partielle pour les études IND120181 et IND135403 sur le palovarotène Pharmaceuticals Other subject
14 Nov 2019
18:00 CET
IPSEN Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company Pharmaceuticals Other subject
14 Nov 2019
18:00 CET
IPSEN Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Pharmaceuticals Other subject